Cargando…
Biotin Interference in Point of Care HIV Immunoassay
The use of high concentrations of biotin as a dietary supplement to improve hair, skin, and nail quality has increased in the United States over the past few years. High concentrations of biotin have been shown to interfere with some diagnostic assays that use streptavidin–biotin interactions as one...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703309/ https://www.ncbi.nlm.nih.gov/pubmed/33269113 http://dx.doi.org/10.1089/biores.2020.0038 |
_version_ | 1783616623192571904 |
---|---|
author | Haleyur Giri Setty, Mohan Kumar Lee, Sherwin Lathrop, Julia Hewlett, Indira K. |
author_facet | Haleyur Giri Setty, Mohan Kumar Lee, Sherwin Lathrop, Julia Hewlett, Indira K. |
author_sort | Haleyur Giri Setty, Mohan Kumar |
collection | PubMed |
description | The use of high concentrations of biotin as a dietary supplement to improve hair, skin, and nail quality has increased in the United States over the past few years. High concentrations of biotin have been shown to interfere with some diagnostic assays that use streptavidin–biotin interactions as one of the steps in the assay. The objective of this report is to evaluate potential biotin interference on the analytical and clinical sensitivity of a point of care (POC) antigen–antibody combo HIV-1 assay. We spiked biotin at concentrations ranging from 12.5 to 400 ng/mL into serum and plasma containing HIV-1 subtype B p24 antigen derived from culture supernatant. The p24 antigen was present in the matrices at 30 pg/mL. Fifty microliters of each sample was applied to Alere Determine HIV-1/2 Ag/Ab combo assay strips in duplicate and results were read by eye after 20 to 30 min. Biotin interfered with detection of HIV-1 p24 in serum and plasma. HIV-1 p24 was not detected at 30 pg/mL p24 when biotin was present at 200 ng/mL concentration. Our study demonstrated that elevated levels of biotin in samples may interfere with POC assays. It is important to consider biotin supplements as potential sources of falsely increased or decreased test results, especially in cases wherein supplementation cannot be ruled out. |
format | Online Article Text |
id | pubmed-7703309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-77033092020-12-01 Biotin Interference in Point of Care HIV Immunoassay Haleyur Giri Setty, Mohan Kumar Lee, Sherwin Lathrop, Julia Hewlett, Indira K. Biores Open Access Original Research Article The use of high concentrations of biotin as a dietary supplement to improve hair, skin, and nail quality has increased in the United States over the past few years. High concentrations of biotin have been shown to interfere with some diagnostic assays that use streptavidin–biotin interactions as one of the steps in the assay. The objective of this report is to evaluate potential biotin interference on the analytical and clinical sensitivity of a point of care (POC) antigen–antibody combo HIV-1 assay. We spiked biotin at concentrations ranging from 12.5 to 400 ng/mL into serum and plasma containing HIV-1 subtype B p24 antigen derived from culture supernatant. The p24 antigen was present in the matrices at 30 pg/mL. Fifty microliters of each sample was applied to Alere Determine HIV-1/2 Ag/Ab combo assay strips in duplicate and results were read by eye after 20 to 30 min. Biotin interfered with detection of HIV-1 p24 in serum and plasma. HIV-1 p24 was not detected at 30 pg/mL p24 when biotin was present at 200 ng/mL concentration. Our study demonstrated that elevated levels of biotin in samples may interfere with POC assays. It is important to consider biotin supplements as potential sources of falsely increased or decreased test results, especially in cases wherein supplementation cannot be ruled out. Mary Ann Liebert, Inc., publishers 2020-11-24 /pmc/articles/PMC7703309/ /pubmed/33269113 http://dx.doi.org/10.1089/biores.2020.0038 Text en © Mohan Kumar Haleyur Giri Setty et al., 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Article Haleyur Giri Setty, Mohan Kumar Lee, Sherwin Lathrop, Julia Hewlett, Indira K. Biotin Interference in Point of Care HIV Immunoassay |
title | Biotin Interference in Point of Care HIV Immunoassay |
title_full | Biotin Interference in Point of Care HIV Immunoassay |
title_fullStr | Biotin Interference in Point of Care HIV Immunoassay |
title_full_unstemmed | Biotin Interference in Point of Care HIV Immunoassay |
title_short | Biotin Interference in Point of Care HIV Immunoassay |
title_sort | biotin interference in point of care hiv immunoassay |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703309/ https://www.ncbi.nlm.nih.gov/pubmed/33269113 http://dx.doi.org/10.1089/biores.2020.0038 |
work_keys_str_mv | AT haleyurgirisettymohankumar biotininterferenceinpointofcarehivimmunoassay AT leesherwin biotininterferenceinpointofcarehivimmunoassay AT lathropjulia biotininterferenceinpointofcarehivimmunoassay AT hewlettindirak biotininterferenceinpointofcarehivimmunoassay |